Compare MUJ & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MUJ | AKBA |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 662.2M | 729.1M |
| IPO Year | 1998 | 2014 |
| Metric | MUJ | AKBA |
|---|---|---|
| Price | $12.47 | $1.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $5.92 |
| AVG Volume (30 Days) | 98.7K | ★ 3.3M |
| Earning Date | 01-01-0001 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $47.43 |
| Revenue Next Year | N/A | $17.65 |
| P/E Ratio | ★ N/A | $40.17 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.50 | $1.14 |
| 52 Week High | $12.50 | $4.08 |
| Indicator | MUJ | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 66.55 | 36.12 |
| Support Level | $11.93 | N/A |
| Resistance Level | $12.48 | $1.57 |
| Average True Range (ATR) | 0.11 | 0.10 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 91.11 | 14.13 |
BlackRock MuniHoldings New Jersey Quality Fund Inc is a non-diversified, closed-end management investment company. Its investment objective is to provide shareholders with current income exempt from U.S. federal income tax and New Jersey personal income taxes. The fund mainly invests in long-term, investment-grade municipal obligations exempt from U.S federal income taxes (except that the interest may be subject to the U.S. federal alternative minimum tax) and New Jersey personal income taxes, with remaining maturities of one year or more at the time of investment. The rest of its managed assets can be invested in securities that are rated below investment grade (or similar instruments), or invested directly in securities or synthetically through the use of derivatives.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.